Skip to main content

Advertisement

Log in

Autoimmune hepatitis after high-dose intravenous glucocorticoids for Graves’ orbitopathy

  • Letter
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marino M, Vaidya B, Wiersinga WM (2021) The 2021 European group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves’ orbitopathy. Eur J Endocrinol 185:G43–G67

    Article  CAS  PubMed  Google Scholar 

  2. Sisti E, Coco B, Menconi F, Leo M, Rocchi R, Latrofa F, Profilo MA, Mazzi B, Vitti P, Marcocci C, Brunetto M, Marinò M (2015) Age and dose are major risk factors for liver damage associated with intravenous glucocorticoid pulse therapy for Graves’ orbitopathy. Thyroid 25:846–850

    Article  CAS  PubMed  Google Scholar 

  3. Mieli-Vergani G, Vergani D, Czaja AJ, Manns MP, Krawitt EL, Vierling JM, Lohse AW, Montano-Loza AJ (2018) Autoimmune hepatitis. Nat Rev Dis Primers 12(4):18017

    Article  Google Scholar 

  4. Lanzolla G, Puccinelli L, Giudetti M, Comi S, Menconi F, Maglionico MN, Posarelli C, Figus M, Marcocci C, Marinò M (2023) Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy. J Endocrinol Invest 46:337–344

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Marinò.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in the study involving human participants were in accordance with the ethical standards of the Trust and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Being a retrospective investigation, ethical approval was not required.

Informed consent

Informed consent was obtained from the individual participant included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cosentino, G., Comi, S., Coco, B. et al. Autoimmune hepatitis after high-dose intravenous glucocorticoids for Graves’ orbitopathy. J Endocrinol Invest 46, 849–850 (2023). https://doi.org/10.1007/s40618-023-02029-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-023-02029-z

Keywords

Navigation